News
Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5h
Zacks Investment Research on MSNNovo Nordisk Rises 6% So Far in August: How to Play the Stock
Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...
1d
Zacks Investment Research on MSNNovo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
2d
Zacks.com on MSNCan Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...
The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, ...
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results